SCHEMBL2935357

SCHEMBL2935357

CC1CCC(C(C)C)C(OP(=O)(O)O)C1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
LMNA P02545 4/20 0.57
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 2/20 0.48
EPHX1 P07099 3/20 0.48
TRPA1 O75762 2/20 0.47
TRPM8 Q7Z2W7 2/20 0.47
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HPGD P15428 1/20 0.44
CYP19A1 P11511 2/20 0.43
APOBEC3A P31941 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
NFE2L2 Q16236 1/20 0.43
KCNA5 P22460 1/20 0.41
INPP5A Q14642 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937641 1.00 ALDH1A1 (0.57) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL9484139 0.90 ALDH1A1 (0.57) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL8988924 0.87 ALDH1A1 (0.52) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL15647383 0.87 ALDH1A1 (0.52) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL8988670 0.87 ALDH1A1 (0.52) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL8988919 0.87 ALDH1A1 (0.55) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL11352601 0.86 ALDH1A1 (0.60) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL8987733 0.85 ALDH1A1 (0.50) ALDH1A1LMNAMEN1KMT2AKDM4E
Citric Acid SCHEMBL8988622 0.83 ALDH1A1 (0.46) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL8988667 0.83 ALDH1A1 (0.57) ALDH1A1LMNAMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100512791-C Oral products having an aesthetic layer PROCTER & GAMBLE (US) 2009-07-15 CN claimed
US-6916463-B2 Oral products having an aesthetic layer THE PROCTER & GAMBLE COMPANY (US) 2005-07-12 US claimed
US-20040057910-A1 Oral products having an aesthetic layer THE PROCTER & GAMBLECOMPANY 2004-03-25 US claimed
EP-0845217-A1 Inhibiting undesirable taste in oral compositions THE PROCTER & GAMBLE COMPANY (US) 1998-06-03 EP claimed
US-5628986-A TOOTHPASTES, MOUTHRINSES, DENTIFRICES, LOZENGES, GUMS CONTAINING PHOSPHATE DERIVATIVE AND COPPER SOURCE THE PROCTER & GAMBLE COMPANY (US) 1997-05-13 US claimed
WO-1996015768-A1 ORAL COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1996-05-30 WO claimed
US-20240209008-A1 METHOD FOR PRODUCING ASYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING SYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING PHOSPHORIC ACID ESTER, AND METHOD FOR PRODUCING ORGANOPHOSPHORUS COMPOUND TOKYO INSTITUTE OF TECHNOLOGY (JP) 2024-06-27 US disclosed
EP-4303222-A1 METHOD FOR PRODUCING ASYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING SYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING PHOSPHORIC ACID ESTER, AND METHOD FOR PRODUCING ORGANOPHOSPHORUS COMPOUND Tokyo Institute of Technology (JP) 2024-01-10 EP disclosed
CN-116917301-A Method for producing asymmetric phosphotriester, method for producing symmetric phosphotriester, method for producing phosphate, and method for producing organic phosphorus compound 国立大学法人东京工业大学 2023-10-20 CN disclosed
EP-3344265-A1 TOPICAL ANTIVIRAL COMPOSITIONS Topical Remedy, LLC (US) 2018-07-11 EP disclosed
WO-2017040844-A1 TOPICAL ANTIVIRAL COMPOSITIONS TOPICAL REMEDY, LLC (US) 2017-03-09 WO disclosed
WO-2012164061-A2 COSMETIC PREPARATIONS AGAINST DANDRUFF LABORATORIOS MIRET, S.A. (ES) 2012-12-06 WO disclosed
CN-101909582-A Oral care delivery system with microcrystalline wax PROCTER & GAMBLE 2010-12-08 CN disclosed
EP-0725630-A1 FAST DISSOLVING DOSAGE FORMS CONTAINING MAGNESIUM ALUMINUM SILICATE AND MULTIPLE ACTIVE INGREDIENTS THE PROCTER & GAMBLE COMPANY (US) 1996-08-14 EP disclosed
EP-0719129-A1 PYROPHOSPHATE DIESTERS FOR TARTAR CONTROL THE PROCTER & GAMBLE COMPANY (US) 1996-07-03 EP disclosed
EP-0719128-A1 COMPOSITION CONTAINING PHOSPHATE DERIVATIVES THE PROCTER & GAMBLE COMPANY (US) 1996-07-03 EP disclosed
WO-1996015768-A1 ORAL COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1996-05-30 WO disclosed
WO-1995011671-A1 FAST DISSOLVING DOSAGE FORMS CONTAINING MAGNESIUM ALUMINUM SILICATE AND MULTIPLE ACTIVE INGREDIENTS THE PROCTER & GAMBLE COMPANY (US) 1995-05-04 WO disclosed
WO-1995007684-A1 PYROPHOSPHATE DIESTERS FOR TARTAR CONTROL THE PROCTER & GAMBLE COMPANY (US) 1995-03-23 WO disclosed
WO-1995007683-A1 COMPOSITION CONTAINING PHOSPHATE DERIVATIVES THE PROCTER & GAMBLE COMPANY (US) 1995-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040057910-A1 Oral products having an aesthetic layer CUTA, LPL, SUCLG1 ALDH1A1 386/4885LMNA 1368/4885MEN1 3713/4885
US-20240209008-A1 METHOD FOR PRODUCING ASYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING SYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING PHOSPHORIC ACID ESTER, AND METHOD FOR PRODUCING ORGANOPHOSPHORUS COMPOUND HAO2, PLCB1, PHPT1 ALDH1A1 1559/4885LMNA 4235/4885MEN1 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.